Biohaven’s ion channel drug fails pivotal bipolar mania study

Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report. The Phase 2/3 study included an estimated 256 people who were voluntarily hospitalized ...

Mar 3, 2025 - 19:22

Biohaven’s ion channel drug fails pivotal bipolar mania study

Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report. The Phase 2/3 study included an estimated 256 people who were voluntarily hospitalized ...